Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
The reason for the refusal was that the company had not run an “adequate and well-controlled” study but had compared its product with a flu vaccine that “does not reflect the best-available standard of care.”
- Simplified Text
-
The reason for the refusal was that Moderna had not run an adequate and well-controlled study and compared its product with a flu vaccine that does not reflect the best-available standard of care
- Confidence Score
- 0.900
- Claim Maker
- Dr. Prasad’s letter to Moderna
- Context Type
- News Article
- Context Details
-
{ "person": "Dr. Prasad", "reason_for_refusal": "inadequate study and comparison with a non-standard vaccine" } - UUID
- a1164c05-75b9-4579-9d6f-0ec03b30a871
- Vector Index
- ✗ No vector
- Created
- February 15, 2026 at 4:02 PM (2 months ago)
- Last Updated
- February 15, 2026 at 4:02 PM (2 months ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
30
claims
🔥
2 months ago
https://nytimes.com/2026/02/10/health/fda-moderna-mrna-flu-vaccine.html
The FDA rejected Moderna's mRNA flu vaccine, signaling a shift in federal health policy under Health Secretary Robert F. Kennedy Jr. The rejection is based on concerns about the clinical trial's comparison product. Moderna's stock has plummeted since its peak.
Similar Claims (0)
Other claims identified as semantically similar to this one.
No similar claims found
This claim appears to be unique in the system.